Finally, the present study results are consistent with the demonstrated therapeutic utility of circadian-timed administration to type 2 diabetes subjects of a quick release formulation of micronized bromocriptine (a dopamine D2 receptor agonist) (Cycloset®), timed to the portion of the day when brain dopamine activity naturally peaks in healthy individuals to improve insulin resistance, glucose intolerance, hyperglycemia and CVD event rate in type 2 diabetes subjects [71]. Here, DRD2 is linked to Glucose intolerance.